As drug modalities grow more complex, low bioburden powders for reconstitution are emerging as a critical strategy to ensure sterility, stability, and scalability.
Christine Allen, CEO and Co-Founder of Intrepid Labs, and Andy Lewis, CSO at Quotient Sciences, highlight their strategic partnership to accelerate drug product development with AI and ML technologies.
Kindeva Drug Delivery is a global contract development and manufacturing organization focused on drug-device combination products. We develop and manufacture products across a broad range of drug-delivery formats, including pulmonary and nasal, injectable, and transdermal. Our service offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from our state-of-the-art manufacturing, research, and development facilities located across the U.S. and U.K.
Pace® makes the world a safer, healthier place. We advance the science of our pharmaceutical and biopharmaceutical customers through the drug development process, from early-phase R&D through clinical trials and GMP commercial product support. For customers with in-house manufacturing and labs, we provide support through professional services.
